Exploiting the cytoskeletal filaments of neoplastic cells to potentiate a novel therapeutic approach - PubMed (original) (raw)
Review
. 2014 Dec;1846(2):599-616.
doi: 10.1016/j.bbcan.2014.09.007. Epub 2014 Oct 5.
Affiliations
- PMID: 25286320
- DOI: 10.1016/j.bbcan.2014.09.007
Free article
Review
Exploiting the cytoskeletal filaments of neoplastic cells to potentiate a novel therapeutic approach
Matthew Trendowski. Biochim Biophys Acta. 2014 Dec.
Free article
Abstract
Although cytoskeletal-directed agents have been a mainstay in chemotherapeutic protocols due to their ability to readily interfere with the rapid mitotic progression of neoplastic cells, they are all microtubule-based drugs, and there has yet to be any microfilament- or intermediate filament-directed agents approved for clinical use. There are many inherent differences between the cytoskeletal networks of malignant and normal cells, providing an ideal target to attain preferential damage. Further, numerous microfilament-directed agents, and an intermediate filament-directed agent of particular interest (withaferin A) have demonstrated in vitro and in vivo efficacy, suggesting that cytoskeletal filaments may be exploited to supplement chemotherapeutic approaches currently used in the clinical setting. Therefore, this review is intended to expose academics and clinicians to the tremendous variety of cytoskeletal filament-directed agents that are currently available for further chemotherapeutic evaluation. The mechanisms by which microfilament directed- and intermediate filament-directed agents damage malignant cells are discussed in detail in order to establish how the drugs can be used in combination with each other, or with currently approved chemotherapeutic agents to generate a substantial synergistic attack, potentially establishing a new paradigm of chemotherapeutic agents.
Keywords: Actin; Chemotherapy; Drug synergy; Intermediate filaments; Microfilaments.
Copyright © 2014. Published by Elsevier B.V.
Similar articles
- Preferential enlargement of leukemia cells using cytoskeletal-directed agents and cell cycle growth control parameters to induce sensitivity to low frequency ultrasound.
Trendowski M, Wong V, Zoino JN, Christen TD, Gadeberg L, Sansky M, Fondy TP. Trendowski M, et al. Cancer Lett. 2015 May 1;360(2):160-70. doi: 10.1016/j.canlet.2015.02.001. Epub 2015 Feb 7. Cancer Lett. 2015. PMID: 25667120 - Targeting the plasma membrane of neoplastic cells through alkylation: a novel approach to cancer chemotherapy.
Trendowski M, Fondy TP. Trendowski M, et al. Invest New Drugs. 2015 Aug;33(4):992-1001. doi: 10.1007/s10637-015-0263-1. Epub 2015 Jun 23. Invest New Drugs. 2015. PMID: 26095786 Free PMC article. Review.
Cited by
- Long-term zinc treatment alters the mechanical properties and metabolism of prostate cancer cells.
Navratil J, Kratochvilova M, Raudenska M, Balvan J, Vicar T, Petrlakova K, Suzuki K, Jadrna L, Bursa J, Kräter M, Kim K, Masarik M, Gumulec J. Navratil J, et al. Cancer Cell Int. 2024 Sep 11;24(1):313. doi: 10.1186/s12935-024-03495-y. Cancer Cell Int. 2024. PMID: 39261823 Free PMC article. - Basal-epithelial subpopulations underlie and predict chemotherapy resistance in triple-negative breast cancer.
Inayatullah M, Mahesh A, Turnbull AK, Dixon JM, Natrajan R, Tiwari VK. Inayatullah M, et al. EMBO Mol Med. 2024 Apr;16(4):823-853. doi: 10.1038/s44321-024-00050-0. Epub 2024 Mar 13. EMBO Mol Med. 2024. PMID: 38480932 Free PMC article. - Cytochalasans and Their Impact on Actin Filament Remodeling.
Lambert C, Schmidt K, Karger M, Stadler M, Stradal TEB, Rottner K. Lambert C, et al. Biomolecules. 2023 Aug 15;13(8):1247. doi: 10.3390/biom13081247. Biomolecules. 2023. PMID: 37627312 Free PMC article. Review. - Cucurbitacin B Down-Regulates TNF Receptor 1 Expression and Inhibits the TNF-α-Dependent Nuclear Factor κB Signaling Pathway in Human Lung Adenocarcinoma A549 Cells.
Kusagawa E, Okuda C, Yamaguchi R, Nakano K, Miyake Y, Kataoka T. Kusagawa E, et al. Int J Mol Sci. 2022 Jun 27;23(13):7130. doi: 10.3390/ijms23137130. Int J Mol Sci. 2022. PMID: 35806134 Free PMC article. - Obstacles to Glioblastoma Treatment Two Decades after Temozolomide.
Cruz JVR, Batista C, Afonso BH, Alexandre-Moreira MS, Dubois LG, Pontes B, Moura Neto V, Mendes FA. Cruz JVR, et al. Cancers (Basel). 2022 Jun 30;14(13):3203. doi: 10.3390/cancers14133203. Cancers (Basel). 2022. PMID: 35804976 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources